Omega Fund Management, LLC

Position in ENGN — enGene Therapeutics Inc.

CIK 1637359 Boston, MA

Position in ENGN

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$1,516,097

-$4,451,894 QoQ

Shares Held

876,357

0.0% QoQ

Ownership

1.31%

of shares outstanding

% of Portfolio

0.82%

of 13F equity value

Holder Rank

#13

of 60 holders

Holding Since

Dec 2023

11 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Omega Fund Management, LLC holds $139,057,890 across 8 Biotechnology names. ENGN ranks #7 (1.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	BCAX	Bicara Therapeutics Inc.	1,822,150	$54,099,633
2	NUVB	Nuvation Bio Inc.	8,081,089	$45,900,585
3	BBOT	BridgeBio Oncology Therapeutics, Inc.	3,289,661	$25,067,216
4	ALMS	Alumis Inc.	241,255	$6,788,915
5	SANA	Sana Biotechnology, Inc.	843,750	$2,944,687
6	IMA	ImageneBio, Inc.	455,361	$2,686,629
7	ENGN	enGene Therapeutics Inc. This page	876,357	$1,516,097
8	ODTX	Odyssey Therapeutics, Inc.	2,893	$54,128

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,516,097	876,357	0.0%	Shares	Sole	2026-08-14
2026-03-31	$5,967,991	876,357	0.0%	Shares	Sole	2026-05-15
2025-12-31	$7,913,503	876,357	+66.5%	Shares	Sole	2026-02-17
2025-09-30	$3,595,018	526,357	0.0%	Shares	Sole	2025-11-14
2025-06-30	$1,915,939	526,357	0.0%	Shares	Sole	2025-08-14
2025-03-31	$2,358,079	526,357	0.0%	Shares	Sole	2025-05-15
2024-12-31	$3,500,274	526,357	-51.1%	Shares	Sole	2025-02-14
2024-09-30	$7,103,956	1,076,357	0.0%	Shares	Sole	2024-11-14
2024-06-30	$10,150,046	1,076,357	0.0%	Shares	Sole	2024-08-14
2024-03-31	$18,244,251	1,076,357	-4.8%	Shares	Sole	2024-05-14
2023-12-31	$10,440,745	1,131,175	—	Shares	Sole	2024-02-14
No filing history on record for this holder in this stock.